Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs

IF 23.7 Q1 MICROBIOLOGY
iMeta Pub Date : 2024-03-13 DOI:10.1002/imt2.179
Huahui Ren, Zhun Shi, Fangming Yang, Shujie Wang, Fengyi Yuan, Tingting Li, Min Li, Jiahui Zhu, Junhua Li, Kui Wu, Yifei Zhang, Guang Ning, Karsten Kristiansen, Weiqing Wang, Yanyun Gu, Huanzi Zhong
{"title":"Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs","authors":"Huahui Ren,&nbsp;Zhun Shi,&nbsp;Fangming Yang,&nbsp;Shujie Wang,&nbsp;Fengyi Yuan,&nbsp;Tingting Li,&nbsp;Min Li,&nbsp;Jiahui Zhu,&nbsp;Junhua Li,&nbsp;Kui Wu,&nbsp;Yifei Zhang,&nbsp;Guang Ning,&nbsp;Karsten Kristiansen,&nbsp;Weiqing Wang,&nbsp;Yanyun Gu,&nbsp;Huanzi Zhong","doi":"10.1002/imt2.179","DOIUrl":null,"url":null,"abstract":"<p>The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":null,"pages":null},"PeriodicalIF":23.7000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.179","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.

Abstract Image

解密人类肠道微生物群与口服抗糖尿病药物之间独特和共同的相互作用
2 型糖尿病患者服用口服抗糖尿病药物(OADs)后,肠道微生物群会发生不同的共同变化,其中阿卡波糖和小檗碱对肠道微生物群的影响大于二甲双胍、维达列汀和格列吡嗪。基线肠道微生物群与 OADs 的治疗反应密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
10.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信